The predictive value of epidermal growth factor receptor (EGFR) protein expression has been debated since the introduction of anti-EGFR antibody therapies for the treatment of colorectal cancer [1] Even today, the protocol of cetuximab/Erbitux (but not of panitumumab/Vectibix) states that the drug can be used to treat EGFR-positive colorectal cancer [2]. The gene discussed is EGFR; the disease is colorectal cancer.